Nomura Holdings’s Cytokinetics CYTK Stock Holding History

Nomura Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.1M	Buy	259,000 +4,800	+2%	+$305K	0.05%	288
2025 Q4	$16.2M	Buy	254,200 +5,000	+2%	+$311K	0.02%	375
2025 Q3	$13.7M	Buy	249,200 +194,700	+357%	+$8.02M	0.02%	415
2025 Q2	$1.8M	Sell	54,500 -3,000	-5%	-$104K	﹤0.01%	862
2025 Q1	$2.31M	Sell	57,500 -463,000	-89%	-$21.3M	﹤0.01%	1004
2024 Q4	$24.5M	Buy	520,500 +400,500	+334%	+$20.8M	0.03%	271
2024 Q3	$6.34M	Sell	120,000 -50,000	-29%	-$2.79M	0.01%	575
2024 Q2	$9.21M	Buy	170,000 +50,000	+42%	+$3.02M	0.02%	473
2024 Q1	$8.41M	Buy	120,000 +37,600	+46%	+$2.91M	0.02%	493
2023 Q4	$6.88M	Buy	+82,400	New	+$2.98M	0.02%	567
2014 Q2	–	Sell	-22,500	Closed	-$213K	–	2790
2014 Q1	$213K	Buy	+22,500	New	+$204K	﹤0.01%	2299

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nomura Holdings's CYTK Position: Q1 2026 in Review

Nomura Holdings reduced its Cytokinetics (CYTK) stake by 94% in Q1 2026, selling an estimated $3.95M and leaving 4,130 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

Nomura Holdings first reported a position in CYTK in Q1 2014 and has held it in 12 quarters since. The position peaked at $7.76M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Nomura Holdings held 4,130 shares of Cytokinetics worth $272K as of Q1 2026.
Nomura Holdings sold 62,077 Cytokinetics shares in Q1 2026, an estimated $3.95M.
Cytokinetics made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1510 holding.
Nomura Holdings first reported a position in Cytokinetics in Q1 2014 and has held it in 12 quarters since.
Nomura Holdings's Cytokinetics position peaked at $7.76M in Q3 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.